# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

> **NCT06556394** · PHASE1 · RECRUITING · sponsor: **Ractigen Therapeutics.** · enrollment: 32 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** RAG-17
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06556394
- **Lead sponsor:** Ractigen Therapeutics.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2026-02
- **Final completion:** 2026-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06556394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06556394, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06556394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*